“Rising Adoption of Biomarker-Based Diagnostics”
The use of biomarker-based diagnostics in Testicular Germ Cell Tumors (TGCT) is becoming more prevalent, with biomarkers such as alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH) playing a crucial role in clinical practice. These biomarkers enable clinicians to achieve early detection, monitor disease progression, and tailor treatments to the individual characteristics of each patient. This trend reflects advancements in precision medicine and is leading to more accurate staging and risk stratification of TGCT. As research continues to identify additional biomarkers, the integration of these diagnostic tools is becoming a standard approach, enhancing treatment protocols and improving patient outcomes.
